The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.
E. Van Cutsem
Research Funding - Roche; Sanofi
C. Boni
Consultant or Advisory Role - Sanofi
J. Tabernero
Consultant or Advisory Role - Roche; Sanofi
B. Massuti
Consultant or Advisory Role - Roche
D. A. Richards
No relevant relationships to disclose
H. Prenen
No relevant relationships to disclose
I. Steinberg
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
P. Rougier
Consultant or Advisory Role - Sanofi